These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24265073)

  • 1. 18F-FDG PET/CT impact on testicular tumours clinical management.
    Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
    Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
    Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
    Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: 18F-FDG PET/CT Impact on Testicular Tumours Clinical Management.
    Richie JP
    J Urol; 2015 Oct; 194(4):991. PubMed ID: 26382779
    [No Abstract]   [Full Text] [Related]  

  • 6. Can we rely on PET in the follow-up of advanced seminoma patients?
    Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
    Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
    Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging in testicular tumours.
    Calabrò D; Telo S; Ambrosini V
    Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
    Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
    Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Petrović J; Beatović S; Šobić-Šaranović D; Odalović S; Stojiljković M; Grozdic-Milojevic I; Veljkovic M; Jovanovic D; Artiko V
    Hell J Nucl Med; 2022; 25(1):19-25. PubMed ID: 35388800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
    Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
    Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
    Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.